Tiziana announces submission of amendment to investigational new drug application to advance oral foralumab, a fully human anti-cd3 monoclonal antibody, in patients with crohn's disease

- tiziana is developing the first oral form of foralumab in a convenient capsule to be evaluated in phase 1b clinical study

TLSA Ratings Summary

TLSA Quant Ranking